USA 🇺🇸: AstraZeneca CEO Pascal Soriot explained in an interview with Jim Cramer of CNBC on Tuesday why the pharmaceutical company believes it can nearly double its revenue by 2030.
"Biology is complicated and we are never sure of anything. But we have a high level of confidence that we can get there, and I think this goal forces us to think creatively, be ambitious, and expand," said Soriot. "We have a strong portfolio of existing products, several blockbuster drugs... growing strongly, and we have another 20 medicines to launch, so we should be able to get there."
Bitman
npub1z20…mxwn
2024-06-06 14:40:14
Author Public Key
npub1z204rz2az24ne8xuym9j90dmnh533e03elucjslnsc802wjyrqps6vmxwnPublished at
2024-06-06 14:40:14Event JSON
{
"id": "f95ed26368133034e1db3380a288f2cc84308b38a001e9674bc8bbdb953939a1",
"pubkey": "129f51895d12ab3c9cdc26cb22bdbb9de918e5f1cff98943f3860ef53a441803",
"created_at": 1717677614,
"kind": 1,
"tags": [],
"content": "USA 🇺🇸: AstraZeneca CEO Pascal Soriot explained in an interview with Jim Cramer of CNBC on Tuesday why the pharmaceutical company believes it can nearly double its revenue by 2030.\n\n\"Biology is complicated and we are never sure of anything. But we have a high level of confidence that we can get there, and I think this goal forces us to think creatively, be ambitious, and expand,\" said Soriot. \"We have a strong portfolio of existing products, several blockbuster drugs... growing strongly, and we have another 20 medicines to launch, so we should be able to get there.\"",
"sig": "187c7b331487052f95f993e80064360afd11a633aa0a04da3daf066bc825222503d25442a938fb21a18bb5f225e37fca50e00b53a63db5a546159caa6e32fb4b"
}